Cognitive dysfunction is one of the most typical characteristics in various neurodegenerative
diseases such as Alzheimer's disease and Parkinson's disease (advanced stage). Although …

Mild cognitive impairment (MCI) is rapidly becoming one of the most common clinical
manifestations affecting the elderly. The pathologic and molecular substrate of people …

The multifaceted nature of the pathology of dementia spectrum disorders has complicated
their management and the development of effective treatments. This is despite the fact that …

In early Alzheimer's dementia, there is a need for PET biomarkers of disease progression
with close associations to cognitive dysfunction that may aid to predict further cognitive …

Evidence for cholinergic dysfunction in very early stages of neurodegeneration like mild
cognitive impairment (MCI) is inconclusive. Previous positron emission tomography (PET) …

Purpose Postmortem studies indicate a loss of nicotinic acetylcholine receptor (nAChRs) in
Alzheimer's disease (AD). In order to establish whether these changes in the cholinergic …

The dementia spectrum encompasses a range of disorders with complex diagnosis,
pathophysiology and limited treatment options. Positron emission tomography (PET) …

The positron emission tomography (PET) radioligand (−)-[18 F] flubatine is specific to α 4 β
2⁎ nicotinic acetylcholine receptors (nAChRs) and has promise for future investigation of the …

Since cholinergic dysfunction has been implicated in Alzheimer's disease (AD), the effects of
Aβ plaques on nicotinic acetylcholine receptors (nAChRs) α4β2* subtype were studied …

Objective To compare regional nicotinic cholinergic receptor binding in older adults with
Alzheimer disease (AD) and healthy older adults in vivo and to assess relationships …